Oxurion N.V.
TBGNF
Other OTC0.17
USD
- -
- -
Return %
Stock
S&P500
1Y
-91.50
26.53
3Y
-91.50
76.60
5Y
-91.50
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Thomas Graney
- Full Time Employees
- 27
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Gaston Geenslaan 1 Leuven Belgium 3001
- IPO Date
- Jan 17, 2007
- Website
- oxurion.com
- Similar Companies
- Business
- Oxurion NV (Euronext Brussels: OXUR; OTC: TBGNF), a biopharmaceutical company headquartered in Leuven, Belgium, develops next-generation therapies to preserve vision in patients with retinal disorders including Geographic Atrophy, the leading cause of vision loss in elderly people worldwide, and Age-related Macular Degeneration; it acquires majority stakes in European pharmaceutical subcontractors to build an integrated group serving healthcare stakeholders, including a 72% stake in Axiodis CRO, a specialist in biometrics and clinical data management via its proprietary eCRF platform. The company focuses on cytoprotective targets identified through its CRISPR-based discovery platform for ophthalmic treatments addressing unmet needs in ophthalmology; it operates in the biotechnology sector with approximately 11 employees and targets clinical-stage clients requiring end-to-end solutions from trial design through market access, with activities spanning Europe and the United States. Founded in 1991 as ThromboGenics NV and renamed Oxurion NV in September 2018, the company maintains subsidiaries such as ThromboGenics Inc. and Oncurious NV while enhancing its service portfolio through strategic expansions. In recent developments, Oxurion signed a letter of intent in October 2025 to acquire a majority stake in a French contract research organization specializing in clinical operations, regulatory affairs, medical affairs, scientific communication, and market access, securing exclusivity through December 31, 2025, to create synergies with Axiodis and position itself as a one-stop shop for clinical trial solutions; it completed the Axiodis acquisition earlier and secured a binding €30 million financing facility in December 2025 dedicated to investments in digital and crypto-assets. Previously, negotiations for a French CRO focused on stem cells announced in July 2024 were terminated by mutual agreement in April 2025 due to unresolved financial terms, while discussions for the biometrics CRO initiated in March 2025 progressed toward completion by June 2025.